THE RELATIONSHIP BETWEEN TUMOUR DOSIMETRY AND OTHER PREDICTIVE AND PROGNOSTIC FACTORS IN PATIENTS WITH UNRESECTABLE NEUROENDOCRINE NEOPLASM (NEN) TREATED WITH PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT)

被引：0
|
作者：
Alipour, Ramin [1 ]
机构：
[1] Peter Maccallum Canc Ctr, Melbourne, Vic, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2023年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：31 / 31
页数：1
相关论文
共 50 条
  • [1] Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Progressive Grade 3 Neuroendocrine Neoplasms (NEN)
    Zhang, Jingjing
    Kulkarni, Harshad
    Singh, Aviral
    Niepsch, Karin
    Mueller, Dirk
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [2] Retrospective analysis of Peptide Receptor Radionuclide Therapy (PRRT) in Japanese patients with unresectable neuroendocrine tumor.
    Kobayashi, Noritoshi
    Wild, Damian
    Kaul, Felix
    Ichikawa, Yasushi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Favourable Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Metastatic Rectal Neuroendocrine Neoplasia (NEN)
    Kong, G.
    Grozinsky-Glasberg, S.
    Akhurst, T.
    Hofman, M.
    Meirovitz, A.
    Maimon, O.
    Schwartz, A.
    Michael, M.
    Gross, D. J.
    Hicks, R.
    NEUROENDOCRINOLOGY, 2018, 106 : 247 - 247
  • [4] Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN)
    Kong, Grace
    Grozinsky-Glasberg, Simona
    Hofman, Michael S.
    Akhurst, Tim
    Meirovitz, Amichay
    Maimon, Ofra
    Krausz, Yodphat
    Godefroy, Jeremy
    Michael, Michael
    Gross, David J.
    Hicks, Rodney J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (03) : 718 - 727
  • [5] Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN)
    Grace Kong
    Simona Grozinsky-Glasberg
    Michael S. Hofman
    Tim Akhurst
    Amichay Meirovitz
    Ofra Maimon
    Yodphat Krausz
    Jeremy Godefroy
    Michael Michael
    David J. Gross
    Rodney J. Hicks
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 718 - 727
  • [6] The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with 177Lu DOTATATE (LuTate)
    Alipour, R.
    Jackson, P.
    Bressel, M.
    Hogg, A.
    Callahan, J.
    Hicks, R. J.
    Kong, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (10) : 2997 - 3010
  • [7] The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with 177Lu DOTATATE (LuTate)
    R. Alipour
    P. Jackson
    M. Bressel
    A. Hogg
    J. Callahan
    R. J. Hicks
    G. Kong
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 2997 - 3010
  • [8] The value of dosimetry in Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumors: literature and practical aspects
    Di Dia, Amalia
    Ferrari, Mahila E.
    Travaini, Laura Lavinia
    Grappeja, Lorenza
    Guglielmo, Priscilla
    Barone, Antonio
    Mei, Riccardo
    Papi, Stefano
    Ceci, Francesco
    Grana, Chiara Maria
    CLINICAL AND TRANSLATIONAL IMAGING, 2025, : 121 - 129
  • [9] Characteristics and Outcomes of Therapy-Related Myeloid Neoplasms after Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Neoplasm (NEN): A Single Centre Series
    Goncalves, I
    Burbury, K.
    Westerman, D.
    Blombery, P.
    Tiong, I. S.
    Iravani, A.
    Ravikumar, A.
    Michael, M.
    Hofman, M.
    Akhurst, T.
    Hicks, R.
    Kong, G.
    NEUROENDOCRINOLOGY, 2019, 108 : 212 - 212
  • [10] Clinical Efficacy of Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Neoplasm
    Zacho, M. D.
    Iversen, P.
    Villadsen, G. E.
    Arveschoug, A. K.
    Grembwk, H.
    Dam, G.
    NEUROENDOCRINOLOGY, 2020, 110 : 279 - 279
12345